CTX-I Detection Service

C-terminal telopeptide of type I collagen, which is also known as carboxy-terminal collagen I crosslinks (CTX-I), is a biomarker that can be measured as an indication of bone resorption changes and bone diseases. Creative BioMart Biomarker offers high quality detection service for CTX-I, ensuring high detection accuracy, sensitivity and efficiency for each sample.

Introduction

CTX-I is a telopeptide product from the breakdown of type I collagen which contains pyridinium crosslinks. Type I collagen is the most abundant collagen in the human body which is expressed in almost all connective tissues. Type I collagen is an important component of structural proteins in tissues such as bone, skin, tendon, ligament and blood vessels, it accounts for about 95% of the total collagen present in bone and accounts for about 80% of the entire proteins exist in bone. Type I collagen is a triple helix that mainly composed of two α1 chains and one α2 chain. When bone resorption occurs, osteoclasts secrete proteolytic enzymes that degrade type I collagen into fragments, obtain CTX-I and NTX-I finally. Therefore, measuring the expression level of CTX-I in the body can reflect the changes of bone resorption rate, CTX-I can be considered as a biomarker for bone resorption and bone diseases. When osteoclasts degrade type I collagen, CTX-I with different fragment sizes is released into the circulation, most of which are relatively small, they can enter the urine through glomerulus, so urine can be added as a test sample for CTX-I. As bone age increases, the aspartic acid present in CTX-I is converted from its α form to the β form, and β-CTX is then released into the blood and can be used as a specific biomarker for bone resorption. The International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry recommend CTX-I as a reference biomarker, in addition, CTX-I can be used as a biomarker for many diseases that are associated with accelerated bone resorption, such as hyperthyroidism, hyperparathyroidism, osteomalacia, rickets, Paget’s disease, multiple myeloma, and bone metastases. As a biomarker for bone diseases, the concentration changes of CTX-I may play a role as an assessment indicator for bone diseases diagnostic and antiresorptive therapies.

CTX-I Detection ServiceFigure 1. A schematic diagram to show the main factors that regulate bone remodeling at cellular level and the generation of bone turnover markers during bone remodeling (Glendenning, et al. 2018)

Application of CTX-I Detection

  • Serum and urine PICP levels as biomarkers to predict different diseases, such as osteomalacia, osteoporosis, bone metastasis, Paget’s disease, multiple myeloma, etc.

Our Advantages

  • Guarantee high accuracy and sensitivity for PICP detection
  • Ensure high repeatability of PICP detection
  • Short turn-around time of detection service
  • Competitive price in the market of detection services
  • Provide multiple PICP detection methods, including ELISA, CLIA and RIA
  • Accept a wide range of sample types (serum and urine)

Workflow of CTX-I Detection at Creative BioMart Biomarker

Creative BioMart Biomarker strictly controls each specific experimental step in the CTX-I detection procedure to ensure accurately quantify the level of CTX-I in each sample.

CTX-I Detection Service

At Creative BioMart Biomarker, we offer CTX-I detection service which includes several technical methods, you can communicate with our experts according to your research needs, and we will determine the final detection technological scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.

References:

  1. Glendenning, P.; et al. Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults. Clinica Chimica Acta. 2018, 481: 161-170.
  2. Szulc, P.; et al. Use of CTX-I and PINP as bone turnover markers: national bone health alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporosis International. 2017, 28: 2541-2556.
  3. Herrmann, M.; Seibel, M. The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX- I and CTX- I: A comparative review. Clinica Chimica Acta. 2008, 393(2): 57-75.

Menu

Contact Us

Subscribe

Enter your email here to subscribe